2017 Fiscal Year Final Research Report
Analysis of ADAM28 activity mechanism on the cell surface
| Project/Area Number |
15K08409
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | National Defense Medical College (2016-2017)
Keio University (2015) |
|---|
Principal Investigator |
Mochizuki Satsuki 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究施設、病院並びに防衛, 外科学, 助教 (80365428)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | ＡＤＡＭ２８ / 分子標的薬 / 肺癌 / 増殖 / 転移 |
|---|
| Outline of Final Research Achievements |
We developed a human neutralizing anti-ADAM28 antibody (211-14) from human combinatorial antibody library, and showed that it inhibits ADAM28 activity and IGF-I-induced carcinoma cell proliferation and migration, leading to elongation of survival rate of mice. In addition, combination therapy of antibody 211-14 and docetaxel more effectively improved the survival time than that of bevacizumab and docetaxel.
All these data suggest that our neutralizing antibody 211-14 may be a useful ADAM28 inhibitor for treatment of the non-small cell lung carcinoma patients in the future.
|
| Free Research Field |
実験病理学、生化学
|
